Navigation Links
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
Date:2/16/2012

LAUSANNE, Switzerland and LEXINGTON, Massachusetts, February 16, 2012 /PRNewswire/ --

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm Group (Debiopharm), a group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that Debiopharm has begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 (HSP90) inhibitor Debio 0932. Debiopharm recently successfully completed a Phase Ia dose escalation study with Debio 0932 and has indicated that it expects to initiate a combination Phase I/II study in non-small cell lung cancer patients in the second quarter of 2012.

"Our team has been very pleased with the development of Debio 0932, which has become an important molecule in Debiopharm's pipeline," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "We believe that HSP90 represents an important molecular target in cancer therapy, and we are eager to advance this molecule in the Phase Ib clinical trial, as well in our planned Phase I/II studies, which we hope will yield important new data for the further development of Debio 0932."

"We have been highly impressed with the depth of Debiopharm's development expertise and commitment to furthering Debio 0932 into additional clinical studies in 2012," said Dan Passeri, Curis President and Chief Executive Officer. "Importantly, we continue to be very pleased with the clinical results that have been observed to-date, and we look forward to reporting further progress on this molecule in the future."

About the Phase I Clinical Trial

Debiopharm initiated a Phase I clinical trial in April 2010 that was designed to evaluate the maximum tolerated dose and safety of Debio 0932. The first part of the study (Phase Ia), an open-label,
'/>"/>

SOURCE The Debiopharm Group and Curis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Augurix Diagnostics Receives the 2011 Debiopharm /Valais Award for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease
2. Continuity as Debiopharm Group™ Management Moves Forward
3. The Japanese Cancer Association and Debiopharm Group(TM) Present the JCA-Mauvernay Award to Dr Ogawa and Prof. Maeda for Their Outstanding Oncology Research
4. Debiopharm Group™ and Aurigene Nominate Development Candidate
5. Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025
6. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
7. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
8. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
11. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held medical ... an exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock ... system for the treatment of cancer in ... is the world,s first and only MRI-guided radiation therapy ...
(Date:1/22/2015)... (NYSE: RMD ) today announced results for its ... $423.0 million, a 10 percent increase compared to the quarter ... constant currency basis). Net income was $91.2 million, an increase ... 2013. Diluted earnings per share for the quarter were $0.64, ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
(Date:1/22/2015)... 22, 2015 Padre Murphy's and Owner Tom ... Pro Player Health Alliance (PPHA). The PPHA's passion ... getting everyone, including NFL greats, treated for obstructive sleep apnea ... groups supporting the cause in the valley. The most recent ...
(Date:1/22/2015)... 2015 Angelweddingdress is a famous wedding dress ... customers to follow it on Facebook, Twitter, and Pinterest. The ... gift. Angelweddingdress draws a lottery every week. , Moreover, the ... 28, 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Thousand of ... Medical Care recalled its GranuFlo and NaturaLyte dialysis concentrates ... underway in U.S. District Court, District of Massachusetts, Bernstein ... 20th, the Court has remanded a case filed by ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... ... leading providers of accounts receivable management services, has moved its National Account Service Center ... ... 2010 -- TekCollect, one of the nation’s leading providers of accounts receivable management ...
... Calif. , Jan. 15 Nearly 7,500 registered nurses have ... to be the largest outpouring of RN volunteers in U.S. history, reports ... clock to find locations for the nurses to deploy on the ground ... the NNU program as well. , View the attached volunteer ...
... SAN FRANCISCO , Jan. 15 A Good Idea ... in San Francisco , plans to give $100,000 to ... the Chase Community Giving contest sponsored by JPMorgan Chase & Co. , ... within the Bay Area, we feel that it is of the utmost importance ...
... To meet ... as part of the coordinated United Nations Flash Appeal. , ... United Nations, NY (Vocus) January 15, 2010 -- Estimates that ... by Haiti’s earthquake have led to an urgent appeal to meet their emergency maternal health ...
... , Jan. 15 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp. ... distributing to shareholders an additional supplement (the "Supplement") to the ... previously delivered to shareholders in connection with the Special Meeting ... . The special meeting was originally held to consider a ...
... provides data on sources of public and private funds , ... the level of funding for biomedical research in the United ... study shows. , The same review also found that the ... An analysis of data showed that funding of biomedical research ...
Cached Medicine News:Health News:TekCollect Opens New National Account Service Center and Corporate Headquarters 2Health News:Nearly 7,500 RNs Ready to Deploy to Haiti 2Health News:San Francisco Charity A GOOD IDEA to Give $100,000 to Haiti Victims Upon Winning Nationwide Charity Program 2Health News:Appeal Launched for Emergency Assistance to Thousands of Pregnant Women at High Risk in Haiti 2Health News:NUCRYST Announces Distribution of Supplemental Information In Connection with Special Meeting of Shareholders 2Health News:NUCRYST Announces Distribution of Supplemental Information In Connection with Special Meeting of Shareholders 3Health News:NUCRYST Announces Distribution of Supplemental Information In Connection with Special Meeting of Shareholders 4Health News:Money for Biomedical Research Cut in Recent Years 2
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
This fixed-volume digital micropipet is used to accurately measure and transfer 10 microliters of solution....
10L...
Medicine Products: